Welcome

Bristol-Myers to Buy Heart Drug-Maker for $13 Billion (1)

Oct. 5, 2020, 11:23 AM

Bristol-Myers Squibb Co. will buy MyoKardia Inc. for $13.1 billion in cash in a deal to expand its offering of heart drugs.

Bristol-Myers will pay $225 a share, according to a statement Monday from the companies, a premium of 61% over the stock’s Friday closing price. MyoKardia rose 59% in premarket U.S. trading.

With the purchase, Bristol-Myers gets access to MyoKardia’s lead product mavacamten, an experimental drug that treats obstructive hypertrophic cardiomyopathy. Expanding Bristol-Myers’s lineup of heart drugs would help the maker of Opdivo for cancer diversify beyond oncology, an area where much of the industry has focused in recent ...

To read the full article log in.

Learn more about A Bloomberg Law subscription.